Mazdutide

Trial

ClassOxyntomodulin-style dual agonist

Typical routes in papersWeekly SC in trials

Half-life contextWeekly-class in development

EvidencePhase 2/3 obesity and metabolic trials

What it is

Mazdutide is a once-weekly GLP-1/glucagon dual agonist in late-stage metabolic trials, especially in East Asian development programs.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

Trial story: appetite down plus a glucagon nudge to burn more energy.
Same visual as survodutide / cotadutide — dual incretin-glucagon, not a simple Ozempic copy.
Not available as a quality-matched research twin of the trial pen.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

Co-agonism at GLP-1 and glucagon receptors; oxyntomodulin-inspired design.

Possible side effects / caveats

GI effects, heart-rate and glycogen-use questions that come with glucagon agonism.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Trial range (published obesity work)	3–6 mg class weekly in some arms	Weekly SC	Read the actual paper; do not copy blindly

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.